<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html id="nojs" xmlns="http://www.w3.org/1999/xhtml" xmlns:m="http://www.w3.org/1998/Math/MathML" xmlns:og="http://ogp.me/ns#" xml:lang="en-GB" lang="en-GB" xmlns:wb=“http://open.weibo.com/wb”>

<head>

   
  
      
  
                  
  
                  
  
            
  
            
            
    <title>Trials | Full text | The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial</title>
<link rel="shortcut icon" type="image/x-icon" href="/images/icon/10096/favicon.ico" />
<link rel="apple-touch-icon" sizes="72x72" href="/sites/10096/images/70.gif" />
<meta http-equiv="X-UA-Compatible" content="IE=7" />


                
    
		
		
		
		
<!-- <?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:cc="http://web.resource.org/cc/" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">
<cc:Work rdf:about="http://www.trialsjournal.com/content/16/1/70">
<cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
</cc:Work>
<cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
<cc:permits rdf:resource="http://web.resource.org/cc/Reproduction"/>
<cc:permits rdf:resource="http://web.resource.org/cc/Distribution"/>
<cc:requires rdf:resource="http://web.resource.org/cc/Notice"/>
<cc:requires rdf:resource="http://web.resource.org/cc/Attribution"/>
<cc:permits rdf:resource="http://web.resource.org/cc/DerivativeWorks"/>
</cc:License>
<item rdf:about="http://www.trialsjournal.com/content/16/1/70">
<title>The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial</title>
<dc:title>The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial</dc:title>
<dc:creator>Okebe, Joseph</dc:creator>
<dc:creator>Bousema, Teun</dc:creator>
<dc:creator>Affara, Muna</dc:creator>
<dc:creator>DiTanna, GianLuca</dc:creator>
<dc:creator>Eziefula, Alice C</dc:creator>
<dc:creator>Jawara, Musa</dc:creator>
<dc:creator>Nwakanma, Davis</dc:creator>
<dc:creator>Amambua-Ngwa, Alfred</dc:creator>
<dc:creator>Van geertruyden, Jean-Pierre</dc:creator>
<dc:creator>Drakeley, Chris</dc:creator>
<dc:creator>D’Alessandro, Umberto</dc:creator>
<dc:identifier>info:doi/10.1186/s13063-015-0597-1</dc:identifier>
<dc:source>Trials 2015, 16:70</dc:source>
<dc:date>2015-03-01</dc:date>

<prism:publicationName>Trials</prism:publicationName>
<prism:publicationDate>2015-03-01</prism:publicationDate>
<prism:volume>16</prism:volume>
<prism:number>1</prism:number>
<prism:section>Study protocol</prism:section>
<prism:startingPage>70</prism:startingPage>
<prism:copyright>2015 Okebe et al.; licensee BioMed Central.</prism:copyright>
</item>
</rdf:RDF>
 -->
 
 
<meta name="citation_journal_title" content="Trials" />
<meta name="citation_publisher" content="BioMed Central Ltd" />


<meta name="citation_author" content="Joseph Okebe" />
<meta name="citation_author_institution" content="Disease Control & Elimination Theme, Medical Research Council Unit, Fajara, The Gambia" />
<meta name="citation_author" content="Teun Bousema" />
<meta name="citation_author_institution" content="Immunology and Infection Department, London School of Hygiene and Tropical Medicine, London, UK" />
<meta name="citation_author" content="Muna Affara" />
<meta name="citation_author_institution" content="Disease Control & Elimination Theme, Medical Research Council Unit, Fajara, The Gambia" />
<meta name="citation_author" content="GianLuca DiTanna" />
<meta name="citation_author_institution" content="Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population health, London School of Hygiene and Tropical Medicine, London, UK" />
<meta name="citation_author" content="Alice C Eziefula" />
<meta name="citation_author_institution" content="Immunology and Infection Department, London School of Hygiene and Tropical Medicine, London, UK" />
<meta name="citation_author" content="Musa Jawara" />
<meta name="citation_author_institution" content="Disease Control & Elimination Theme, Medical Research Council Unit, Fajara, The Gambia" />
<meta name="citation_author" content="Davis Nwakanma" />
<meta name="citation_author_institution" content="Disease Control & Elimination Theme, Medical Research Council Unit, Fajara, The Gambia" />
<meta name="citation_author" content="Alfred Amambua-Ngwa" />
<meta name="citation_author_institution" content="Disease Control & Elimination Theme, Medical Research Council Unit, Fajara, The Gambia" />
<meta name="citation_author" content="Jean-Pierre Van geertruyden" />
<meta name="citation_author_institution" content="International Health Unit, Faculty of Medicine & Health Sciences, University of Antwerp, Antwerp, Belgium" />
<meta name="citation_author" content="Chris Drakeley" />
<meta name="citation_author_institution" content="Immunology and Infection Department, London School of Hygiene and Tropical Medicine, London, UK" />
<meta name="citation_author" content="Umberto D’Alessandro" />
<meta name="citation_author_institution" content="Disease Control & Elimination Theme, Medical Research Council Unit, Fajara, The Gambia" />
<meta name="citation_author_institution" content="Department of Disease Control, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK" />
<meta name="citation_author_institution" content="Department of Public health, Institute of Tropical Medicine, Antwerp, Belgium" />


<meta name="citation_issn" content="1745-6215" />
<meta name="citation_title" content="The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial" />
<meta name="citation_volume" content="16" />
<meta name="citation_issue" content="1" />
<meta name="citation_date" content="2015-03-01" />
<meta name="citation_firstpage" content="70" />
<meta name="citation_doi" content="10.1186/s13063-015-0597-1" />
<meta name="citation_pdf_url" content="http://www.trialsjournal.com/content/pdf/s13063-015-0597-1.pdf" />
<link rel="alternate" type="application/pdf" title="PDF" href="http://www.trialsjournal.com/content/pdf/s13063-015-0597-1.pdf" />
<meta name="title" content="The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial" />
<meta name="description" content="Finding efficacious tools to decrease and interrupt malaria transmission is essential to sustain the gains in malaria control and contain the emergence of artemisinin resistance. Primaquine is effective against Plasmodium falciparum gametocytes and recommended for treatment campaigns in (pre-)elimination settings. Safety concerns preclude its use in endemic African countries with variable proportions of glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals. The efficacy of the current recommended dose needs to be evaluated, particularly in individuals with an asymptomatic malaria infection." />

<meta name="dc.title" content="The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial" />
<meta name="dc.creator" content="Okebe, Joseph" />
<meta name="dc.creator" content="Bousema, Teun" />
<meta name="dc.creator" content="Affara, Muna" />
<meta name="dc.creator" content="DiTanna, GianLuca" />
<meta name="dc.creator" content="Eziefula, Alice C" />
<meta name="dc.creator" content="Jawara, Musa" />
<meta name="dc.creator" content="Nwakanma, Davis" />
<meta name="dc.creator" content="Amambua-Ngwa, Alfred" />
<meta name="dc.creator" content="Van geertruyden, Jean-Pierre" />
<meta name="dc.creator" content="Drakeley, Chris" />
<meta name="dc.creator" content="D’Alessandro, Umberto" />
<meta name="dc.description" content="Finding efficacious tools to decrease and interrupt malaria transmission is essential to sustain the gains in malaria control and contain the emergence of artemisinin resistance. Primaquine is effective against Plasmodium falciparum gametocytes and recommended for treatment campaigns in (pre-)elimination settings. Safety concerns preclude its use in endemic African countries with variable proportions of glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals. The efficacy of the current recommended dose needs to be evaluated, particularly in individuals with an asymptomatic malaria infection." />
<meta name="dc.source" content="Trials 2015 16:70" />
<meta name="dc.format" content="text/html" />
<meta name="dc.publisher" content="BioMed Central Ltd" />
<meta name="dc.date" content="2015-03-01" />
<meta name="dc.type" content="Study protocol" />
<meta name="dc.identifier" content="10.1186/s13063-015-0597-1" />
<meta name="dc.language" content="en" />
<meta name="dc.copyright" content="2015 Okebe et al.; licensee BioMed Central." />
<meta name="dc.rights" content="http://creativecommons.org/licenses/by/2.0/" />
<meta name="dc.rightsAgent" content="reprints@biomedcentral.com" />

<meta name="prism.issn" content="1745-6215" />
<meta name="prism.publicationName" content="Trials" />
<meta name="prism.publicationDate" content="2015-03-01" />
<meta name="prism.volume" content="16" />
<meta name="prism.number" content="1" />
<meta name="prism.section" content="Study protocol" />
<meta name="prism.startingPage" content="70" />
<meta name="prism.copyright" content="2015 Okebe et al.; licensee BioMed Central." />
<meta name="prism.rightsAgent" content="reprints@biomedcentral.com" />


        <meta name="citation_abstract_html_url" content="http://www.trialsjournal.com/content/16/1/70/abstract" />
            <meta name="citation_fulltext_html_url" content="http://www.trialsjournal.com/content/16/1/70" />
            <link rel='alternate' type='text/xml' title='XML version' href='http://www.trialsjournal.com/content/download/xml/s13063-015-0597-1.xml' />
            <link rel="image_src" href="http://www.trialsjournal.com/content/figures/s13063-015-0597-1-toc.gif" />
    
    
    
    
                    
    

<script type="text/javascript">
// must run before css
document.documentElement.id = "js";
</script>



						
   
  
      
  
                  
  
                  
  
            
  
            
            



						
        <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery-1.8.2.min-0.js"></script>

	                <link rel="stylesheet" type="text/css" href="/css/main-0.css" media="screen, print"/>
    
                <link rel="stylesheet" type="text/css" href="/css/plugins-0.css" media="screen, print"/>
    



    

			                <link rel="stylesheet" type="text/css" href="http://www.bmcimg.com/css/articles-0.css" media="screen, print"/>
    	

    

    <link rel="stylesheet" type="text/css" href="/css/themes/10096.css" media="screen, print"/>


                <link rel="stylesheet" type="text/css" href="/css/media/print-0.css" media="print"/>
    



<!--[if IE]>
                    <link rel="stylesheet" type="text/css" href="/css/hacks/ie-0.css"/>
    <![endif]-->

<!--[if IE 7]>
                    <link rel="stylesheet" type="text/css" href="/css/hacks/ie7-0.css"/>
    <![endif]-->
			
<script type="text/javascript">
    //configuration
    OAS_url = '//oas.biomedcentral.com/RealMedia/ads/';

	// control of advert's position on page [AMC]
    
    	
	
    OAS_sitepage = "trialsjournal.com/article/10.1186/s13063/015/0597/1";
    	
		OAS_listpos = 'Top,x96,Right3';
	
	
			
		OAS_query = '';
		
	

    OAS_target = '_top';
    //end of configuration
    OAS_version = 10;
    OAS_rn = '001234567890'; OAS_rns = '1234567890';
    OAS_rn = new String (Math.random()); OAS_rns = OAS_rn.substring (2, 11);
    function OAS_NORMAL(pos) {
		document.write('<a href="' + OAS_url + 'click_nx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '!' + pos + '?' + OAS_query + '" target="' + OAS_target + '">');
		document.write('<img src="' + OAS_url + 'adstream_nx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '!' + pos + '?' + OAS_query + '" border="0"/></a>');
    }
    
	function refererTerms(referer) {

	if(referer.match("q=") != null) {
		referer = referer.split("q=");
		referer = referer[1].split("&");
		referer = referer[0];
	} else {
		referer = referer;
	}

		if(referer.match("%20") != null && referer.match("%20").length >= 1) {
			referer =  referer.replace(/%20/gi,"+");
			return referer;
		} else { 
			return referer; 
		}
	}
 </script>


 <script type="text/javascript">
	// Set the version of JavaScript to 10 for a Browser 'Mozilla/3' on webTV 
    OAS_version = 11;
    if ((navigator.userAgent.indexOf('Mozilla/3') != -1) || (navigator.userAgent.indexOf('Mozilla/4.0 WebTV') != -1)) {
     OAS_version = 10; }
    if (OAS_version >= 11) {
    document.write('<scr' + 'ipt type="text/javascript" src="' + OAS_url + 'adstream_mjx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '?' + OAS_query + '"><\/script>'); }
</script>
	
<script type="text/javascript">
    document.write('');
	
    function OAS_AD(pos) {
        if (OAS_version >= 11)
         OAS_RICH(pos);
        else
         OAS_NORMAL(pos);
    }
 </script>
	





<script type="text/javascript">
    jsonLoaders = function(){
        var _loaders = [];
        return {
            register: function(config){
                config.prefix = config.prefix || '/webapi/1.0/blogs/';
                config.feedLength = config.feedLength || 3;

                _loaders.push(config);
            },
            list: function(){return _loaders}
        };
    }();

    function totext() {
	    document.write('<a href="javascript:returnToText();">Return to text</a>');
    }

    function retrieve_doi(){
        var metas = document.getElementsByTagName('meta');
        var i;
        for (i = 0; i < metas.length; i++)
            if (metas[i].getAttribute('name') == "citation_doi")
                break;
        var citation_doi = metas[i].getAttribute('content');
        return citation_doi;
    }

</script>





    <script src="http://tjs.sjs.sinajs.cn/open/api/js/wb.js" type="text/javascript" charset="utf-8"></script>
        <link title="Latest articles" rel="alternate" href="http://www.trialsjournal.com/latest/rss" type="application/rss+xml" exposeToHeader="true"/>
    <link title="Most viewed" rel="alternate" href="http://www.trialsjournal.com/mostviewed/rss/" type="application/rss+xml" exposeToHeader="true"/>
    <link title="Latest comments" rel="alternate" href="http://www.trialsjournal.com/latestcomments/rss" type="application/rss+xml" exposeToHeader="true"/>
    


	<script type="text/javascript">
	var _gaq = _gaq || [];
	_gaq.push(['_setAccount', 'UA-9663741-5']);
	_gaq.push(['_gat._anonymizeIp']);
	_gaq.push(['_setLocalRemoteServerMode']);
	
	/*for cross domain tracking*/
	//_gaq.push(['_setAllowLinker', true]);
    //_gaq.push(['_setDomainName', 'trialsjournal.com']); //this journal's domain
	/**/
	
		_gaq.push(['_trackPageview']); 

	(function() {
		var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
		ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
		var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);

		//var iframe = document.getElementById('casesdb-search-widget');
		//if(iframe !== null) {
		//	var pageTracker = _gat._getTrackerByName();
		//	iframe.src = pageTracker._getLinkerUrl('http://www.casesdatabase.com/');
		//}
	})();
	</script>

	
        </head>


<body class=" theme    ">


        



   
  
      
  
                  
  
                  
  
            
  
            
            

    

<div id="oas-campaign" style="display:none">trialsjournal.com/article/10.1186/s13063/015/0597/1</div>
<div id="oas-positions" style="display:none">Bottom,Top</div>

<div id="branding" role="banner">
                			
		<dl class="google-ad wide ">
	<dt class="hide">
					<a class="banner-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising"></a>
				
			</dt>
		<dd>

		<!-- OAS AD 'Top' begin -->
		<script type="text/javascript">
		OAS_AD('Top');

		</script>
		<!-- OAS AD 'Top' end -->
		</dd>

		</dl>

		<noscript>
			<dl class="google-ad wide noscript">  
    <dt class="hide"></dt>
    
    <dd>
        <a href="//oas.biomedcentral.com/RealMedia/ads/click_nx.ads/trialsjournal.com/article/10.1186/s13063/015/0597/1/13205817426@Top?">
            <img src="//oas.biomedcentral.com/RealMedia/ads/adstream_nx.ads/trialsjournal.com/article/10.1186/s13063/015/0597/1/17435523391@Top?" alt="advert"/>
        </a>
    </dd>
			</dl>
		</noscript>
			            <div class="sup-panel-outer">
        <div class="sup-panel-inner">

            <style>
  #nojs li.greeting, #nojs li#loginLink {display:none;}
</style>


<ul id="login" class="login">

    <noscript><li><a href="/log"><img class="greeting" src="/images/log.gif"/></a></li></noscript>
    
    <li id="welcome"><span id="username"></span></li>

    <li id="loginLink"><a href=""></a></li>
    
    
</ul>

<script>

function login() {

/* cookie getter/setter */
var allCookies = {
  getItem: function (sKey) {
    if (!sKey || !this.hasItem(sKey)) { return null; }
    return unescape(document.cookie.replace(new RegExp("(?:^|.*;\\s*)" + escape(sKey).replace(/[\-\.\+\*]/g, "\\$&") + "\\s*\\=\\s*((?:[^;](?!;))*[^;]?).*"), "$1"));
  },
  setItem: function (sKey, sValue, vEnd, sPath, sDomain, bSecure) {
    if (!sKey || /^(?:expires|max\-age|path|domain|secure)$/i.test(sKey)) { return; }
    var sExpires = "";
    if (vEnd) {
      switch (vEnd.constructor) {
        case Number:
          sExpires = vEnd === Infinity ? "; expires=Tue, 19 Jan 2038 03:14:07 GMT" : "; max-age=" + vEnd;
          break;
        case String:
          sExpires = "; expires=" + vEnd;
          break;
        case Date:
          sExpires = "; expires=" + vEnd.toGMTString();
          break;
      }
    }
    document.cookie = escape(sKey) + "=" + escape(sValue) + sExpires + (sDomain ? "; domain=" + sDomain : "") + (sPath ? "; path=" + sPath : "") + (bSecure ? "; secure" : "");
  },
  removeItem: function (sKey, sPath) {
    if (!sKey || !this.hasItem(sKey)) { return; }
    document.cookie = escape(sKey) + "=; expires=Thu, 01 Jan 1970 00:00:00 GMT" + (sPath ? "; path=" + sPath : "");
  },
  hasItem: function (sKey) {
    return (new RegExp("(?:^|;\\s*)" + escape(sKey).replace(/[\-\.\+\*]/g, "\\$&") + "\\s*\\=")).test(document.cookie);
  },
  keys: /* optional method: you can safely remove it! */ function () {
    var aKeys = document.cookie.replace(/((?:^|\s*;)[^\=]+)(?=;|$)|^\s*|\s*(?:\=[^;]*)?(?:\1|$)/g, "").split(/\s*(?:\=[^;]*)?;\s*/);
    for (var nIdx = 0; nIdx < aKeys.length; nIdx++) { aKeys[nIdx] = unescape(aKeys[nIdx]); }
    return aKeys;
  }
};

// converts cookie into js object
function parseCookie(cookie) {

    cookie = cookie.split("&");
    var obj = {};

    for(var i = 0; i < cookie.length; i++) {

        var c = cookie[i].split("=");

        c[0] = c[0].replace('"','');
        
        obj[c[0]] = c[1];

    }
    return obj;
}

    var cookie = allCookies.getItem("bmccookie");

    var obj = (cookie != null) ? parseCookie(cookie) : {};
    

        var welcome = "";

        if(obj.hasOwnProperty("fname")) {

            // insert user welcome
            welcome = obj.fname.replace(/\+/g, " ") + " " + obj['lname'].replace(/\+/g," ");

            if(jQuery("#welcome").length > 0) {
              jQuery("#welcome").prepend("<strong>Welcome</strong> ");
              jQuery("#username").prepend('<strong>' + welcome + '</strong><span class="divider"></span>');
            } 

            // update link url
            jQuery("#loginLink a").text("Log off");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logoff");

            window.bmcloggedon = true;


        } else if(obj.hasOwnProperty("institution_name")) {

            // insert institution name
            welcome = obj["institution_name"].replace(/\+/g," ");
            
            if(jQuery("#welcome").length > 0) { 
                jQuery("#welcome").prepend("<strong>Welcome</strong> ");
                jQuery("#username").prepend('<strong>' + welcome + '</strong><span class="divider"></span>');
            } 

            // update link url
            jQuery("#loginLink a").text("Log on");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logon");

            window.bmcloggedon = false;


        } else {
            jQuery("#welcome").innerHTML = "";
            jQuery("#loginLink a").text("Log on");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logon");

            window.bmcloggedon = false;

        }


        // if athens login cookie doesn't exist and the athens login link is visible then remove it.
        if(allCookies.hasItem("athens") != true && document.getElementById("loginAthensLink") != null) {
          jQuery("#loginAthensLink").hide();
        }

}

login();


</script>

            <ul class="nav-sup">

    
        <li id="BMC" class="current">
            <a href="http://www.biomedcentral.com/"><span class="img-title">&nbsp;</span>
            <span class="text-title">BioMed Central</span></a>
        </li>
		
        		<li><a href="http://www.biomedcentral.com/journals"><span>Journals</span></a></li>
		
								<li>
				<a href="http://www.biomedcentral.com/gateways"><span>Gateways</span></a>
			</li>
					    	
</ul>
        </div>
    </div>
    <div class="branding-inner">

        

    
<style>
.survey {
	margin: 10px 0;
}
.survey, .survey .survey-sentence {
	font-size: 13px;
}
.survey-button a, .survey-button a:active, .survey-button a:visited, .survey-button a:hover  {
    color: #FFFFFF;
    text-decoration: none;
}
.survey-button {
	background-color: #FFA500;
    border-radius: 5px;
    color: #FFFFFF;
    font-weight: bold;
    font-size: 13px;
    font-weight: bold;
    padding: 5px 13px;
    background: #ef8142; /* Old browsers */
	background: -moz-linear-gradient(top,  #ef8142 0%, #ef8142 50%, #a64510 100%, #a64510 100%); /* FF3.6+ */
	background: -webkit-gradient(linear, left top, left bottom, color-stop(0%,#ef8142), color-stop(50%,#ef8142), color-stop(100%,#a64510), color-stop(100%,#a64510)); /* Chrome,Safari4+ */
	background: -webkit-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* Chrome10+,Safari5.1+ */
	background: -o-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* Opera 11.10+ */
	background: -ms-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* IE10+ */
	background: linear-gradient(to bottom,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* W3C */
	filter: progid:DXImageTransform.Microsoft.gradient( startColorstr='#ef8142', endColorstr='#a64510',GradientType=0 ); /* IE6-9 */

}
</style>




          <div class="logo">
        <a href="/"><img alt="Trials" title="Trials Logo" src="/sites/10096/images/logo.gif" /></a>     
      </div>    
        
                    



            <div id="impact-factor" class="official">
    <img src="/images/branding/official.gif" alt="official impact factor" title="2.12"/>
    <span id="impact-factor-value">2.12</span>
</div>
    
                            

<div class="module search gray small  " role="search">
    <div class="module-inner padded">
        <form method="get" class="searchForm"
              action=" /quickSearchRedirectURL "
              onsubmit="window.location.href=this['url'].value + '?terms=' + encodeURIComponent(this['terms'].value); return false;">
            <fieldset class="search">
			                <span>
                    Search <select name="url">
                                <option value="http://www.trialsjournal.com/search/results" selected>Trials</option>
                                <option value="http://www.biomedcentral.com/search/results">BioMed Central</option>
                           </select> for
                </span>
                            <input id="searchTerms" name="terms" type="text" alt="Search terms" class="text " />
                 <button class="w37" value="Go" type="submit">Go</button>
            </fieldset>
        </form>
    </div>
	<a class="advanced-search" href="/search">Advanced search</a>
</div> 

                        <div id="mobile-nav-list" >

	<ul class="primary-nav" role="navigation">
		<li     ><a href="/"><span id="home-tab">Home</span></a></li>
														<li             class="current"
    ><a href="/content"><span id="articles-tab">Articles</span></a></li>
										
	

	
            <li     ><a href="/authors/instructions"><span id="authors-tab">Authors</span></a></li>
        <li     ><a href="/about/reviewers"><span id="reviewers-tab">Reviewers</span></a></li>
    		<li     ><a href="/about"><span id='about-tab'>About this journal</span></a></li>
	<li     ><a href="/my"><span id="my-tab">My Trials</span></a></li>
		
    		</ul>
</div>
            </div>
</div>

<hr class="hide" />
<div class="container">
	<div id="content"  class="overflow-visible"  role="main">
			    
	

<!--div class="branding-mobile">
		<h1 class="logo">
	    <a href="/">
		    <img alt="Trials" title="Trials Logo" src="/sites/10096/images/logo.gif" />
		</a>
		</h1>
	</div><br/-->



			
	



<div class="outline-wrapper block mobile-hidden" id="left-article-box">
<ul id="box-outline" class="box">
<ul id="outline" class="outline">
   <li>
      <a href="#">Top</a>
   </li>
   <li>
      <a href="#abs">Abstract</a>
   </li>
   <li>
      <a href="#sec1">Background</a>
   </li>
   <li>
      <a href="#sec2">Methods</a>
   </li>
   <li>
      <a href="#sec3">Discussion</a>
   </li>
   <li>
      <a href="#sec4">Trial status</a>
   </li>
   <li>
      <a href="#sec5">Abbreviations</a>
   </li>
   <li>
      <a href="#sec6">Competing interests</a>
   </li>
   <li>
      <a href="#sec7">Authors’ contributions</a>
   </li>
   <li>
      <a href="#ack">Acknowledgements</a>
   </li>
   <li class="lowest">
      <a href="#refs">References</a>
   </li>
</ul>
</ul>

<dl id="box-outline1">
</dl>

				



</div>



<div class="mobile-hidden" id="right-panel">
 	
<div id="mobile-sidebar">
	<div id="mobile-sidebar-tab">
		<span>
			<a href="#" id="mobile-sidebar-tab-link"><img src="/images/sidebar-hidden.png"><img style="display:none;" src="/images/sidebar-shown.png"></a>
		</span>
	</div>	<div id="mobile-sidebar-list">

<div id="article-navigation-bar">
    <div class="issue-information block">
        <h5><a href="http://www.trialsjournal.com"><strong>Trials</strong></a></h5>
 		        <ul class="square normal">
            <li><a href="http://www.trialsjournal.com/content/16">Volume 16</a></li>
				
                    </ul>
    </div>

    <div class="article-information block" id="article-info">
        


<div id="viewing-options-links">
	<h5>Viewing options</h5>
	<ul class="square normal">
        
            <li>
                             <a onclick="_gaq.push(['_trackEvent', 'Abstract', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="/content/16/1/70/abstract">Abstract</a>
                        </li>
        				<li>
							<strong>Full text</strong>
					</li>
				
		<li class="pdfFileSize">
			<a onclick="_gaq.push(['_trackEvent', 'PDF download', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="/content/pdf/s13063-015-0597-1.pdf">PDF</a>
			<span>(955KB)</span>
		</li>

                    <li>
                <a onclick="_gaq.push(['_trackEvent', 'e Pub', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="/content/epub/s13063-015-0597-1.epub">ePUB</a>
                (44KB)
            </li>
        
			</ul>

        
</div>
		
<div id="associated-material-links">
    <h5>Associated material</h5>
    <ul class="square normal">
                                    <li><a onclick="_gaq.push(['_trackEvent', 'Article metrics', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="/content/16/1/70/about">Article metrics</a></li>
                <li>
                        <a onclick="_gaq.push(['_trackEvent', 'Readers comments', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="/content/16/1/70/comments">Readers' comments </a>
                    </li>
        <li>
                            <a onclick="_gaq.push(['_trackEvent', 'Pre-publication history', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="/content/16/1/70/prepub">Pre-publication history</a>                    </li>
    </ul>
</div>
		




<div id="related-literature-links">
    <h5>Related literature</h5>
    <ul class="normal">
                    <li><a onclick="_gaq.push(['_trackEvent', 'Citied by', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="http://www.trialsjournal.com/content/16/1/70/about#citations">Cited by</a></li>
                <li id="google-blog-search"><a onclick="_gaq.push(['_trackEvent', 'Google blog search', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="http://www.google.com/search?tbm=blg&hl=en&amp;source=hp&amp;biw=1280&amp;bih=899&amp;q=%22The+gametocytocidal+efficacy+of+primaquine+in+malaria+asymptomatic+carriers+treated+with+dihydroartemisinin-piperaquine+in+The+Gambia+%28PRINOGAM%29%3A+study+protocol+for+a+randomised+controlled+trial%22&amp;btnG=Search">Google blog search</a></li>
        <h6>Other articles by authors</h6>
        <li>
            <a class="collapser"><i>&nbsp;</i>on Google Scholar</a>
<ul id="authg" class="hidebeforeload">                         <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22J+Okebe%22">Okebe J</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22T+Bousema%22">Bousema T</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22M+Affara%22">Affara M</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22GL+DiTanna%22">DiTanna GL</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22AC+Eziefula%22">Eziefula AC</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22M+Jawara%22">Jawara M</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22D+Nwakanma%22">Nwakanma D</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22A+Amambua-Ngwa%22">Amambua-Ngwa A</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22JP+Van geertruyden%22">Van geertruyden JP</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22C+Drakeley%22">Drakeley C</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22U+D’Alessandro%22">D’Alessandro U</a>
            </li>
            </ul>          </li>
                <li>
            	        </li>
    </ul>     <h6>Related articles/pages</h6>
    <ul class="square normal">
        <li><a onclick="_gaq.push(['_trackEvent', 'on google', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="http://www.google.co.uk/search?hl=en&amp;q=related:http://www.trialsjournal.com/content/16/1/70">on Google</a></li>
        <li><a onclick="_gaq.push(['_trackEvent', 'on google scholar', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="http://scholar.google.com/scholar?q=related:http://www.trialsjournal.com/content/16/1/70">on Google Scholar</a></li>
            </ul>

</div>		
        
    
    
        

    	






<h5>Tools</h5>
	<ul class="square normal">
									<li>
						<a onclick="_gaq.push(['_trackEvent', 'download references', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="/content/16/1/70/citation">Download references</a>
					</li>
				<li><a onclick="_gaq.push(['_trackEvent', 'download xml', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="/content/download/xml/s13063-015-0597-1.xml">Download XML</a></li>
				<li>
						<a onclick="_gaq.push(['_trackEvent', 'email2friend', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="/content/16/1/70/email">Email to a friend</a>
					</li>
		<li><a onclick="_gaq.push(['_trackEvent', 'order reprints', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=738&doi=10.1186/s13063-015-0597-1&volume=16&issue=1&title=The+gametocytocidal+efficacy+of+primaquine+in+malaria+asymptomatic+carriers+treated+with+dihydroartemisinin-piperaquine+in+The+Gambia+%28PRINOGAM%29%3A+study+protocol+for+a+randomised+controlled+trial&author_name=Joseph Okebe&start_page=1&end_page=7">Order reprints</a></li>
		<li>
						<a onclick="_gaq.push(['_trackEvent', 'post a comment', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="/content/16/1/70/postcomment">Post a comment</a>
					</li>			
		<ul id="download-to-links">
			<a class="downloadto_title btn" href="#"><span class="icon">&nbsp;</span>Download to ...</a>
			
			<ul id="downloadto" class="iconlist hidebeforeload" style="display: none;">
				<li>
					<a href="http://redirect.papersapp.com/redirect?url=http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F70" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Papers', 'Article Sidebar', '/content/16/1/70', 1, true]);"><span class="share-icons papers"></span>Papers</a>
				</li>
				<li>
					<a href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/70" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Mandeley', 'Article Sidebar', '/content/16/1/70', 1, true]);"><span class="share-icons mendeley"></span>Mendeley</a>
				</li>
			</ul>
		</ul>
		
		<ul id="mobile-downloadto" class="iconlist">
		
		<h6>Download to ...</h6>
			<li>
				<a href="http://redirect.papersapp.com/redirect?url=http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F70" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Papers', 'Article Sidebar', '/content/16/1/70', 1, true]);"><span class="share-icons papers"></span>Papers</a>
			</li>
			
			<li>
				<a href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/70" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Mandeley', 'Article Sidebar', '/content/16/1/70', 1, true]);"><span class="share-icons mendeley"></span>Mendeley</a>
			</li>
		</ul>

		
	</ul>
		




<h5>Share this article</h5>
<ul id="social-networking-links">
	<li>
	<div class="fb-like" onclick="_gaq.push(['_trackEvent', 'Facebook Recommend', 'Article Sidebar', '/content/16/1/70', 1, true]);" data-href="http://www.trialsjournal.com/content/16/1/70" data-send="false" data-layout="button_count" data-width="100" data-show-faces="false" data-action="recommend"></div>
	</li>
	<li>
		<a onclick="_gaq.push(['_trackEvent', 'Share Twitter Recommend', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="http://twitter.com/share" data-url="http://www.trialsjournal.com/content/16/1/70" data-counturl="http://www.trialsjournal.com/content/16/1/70" data-hashtags="trials
" data-text="The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial" class="twitter-share-button">Tweet</a>
	</li>
	<li>
			<g:plusone size="medium" width="100"></g:plusone>
	</li>

        <li>
        <wb:share-button onclick="_gaq.push(['_trackEvent', 'Recommend Google plus', 'Article Sidebar', '/content/16/1/70', 1, true]);" addition="number" type="button" ralateUid="2216240737" title="The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial http://www.trialsjournal.com/content/16/1/70"></wb:share-button>
    </li>
    
		<a class="sharethis_title btn" href="#"><span class="icon">&nbsp;</span>More options...</a>
	<ul class="iconlist hidebeforeload" id="sharethis">
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'citeu Like', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="http://www.citeulike.org/posturl?url=http://www.trialsjournal.com/content/16/1/70"><span class="share-icons citeulike"></span>Citeulike</a>
			</li>
				<li>
			<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share Linkedin', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="http://www.linkedin.com/shareArticle?mini=true&url=%26%2335%3Btrials%0D%0AThe%20gametocytocidal%20efficacy%20of%20primaquine%20in%20malaria%20asymptomatic%20carriers%20treated%20with%20dihydroartemisinin-piperaquine%20in%20The%20Gambia%20%28PRINOGAM%29%3A%20study%20protocol%20for%20a%20randomised%20controlled%20trial%20http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F70&title=The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial"><span class="share-icons linkedin"></span>LinkedIn</a>
	</li>
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share delicious', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="http://del.icio.us/post?url=http://www.trialsjournal.com/content/16/1/70&title=The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial"><span class="share-icons delicious"></span>Del.icio.us</a>
	</li>
			<li>
				<a onclick="_gaq.push(['_trackEvent', 'Share via email', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="/content/16/1/70/email"><span class="share-icons email"></span>Email</a>
	</li>
			<li>
				<a onclick="target="_blank" onclick="_gaq.push(['_trackEvent', 'Share facebook', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="http://www.facebook.com/sharer.php?u=http://www.trialsjournal.com/content/16/1/70"><span class="share-icons facebook"></span>Facebook</a>
	</li>
	<li class="gp">
			<div class="googlehider mobile-hide"> 
				<div class="g-plusone" data-annotation="none"></div>
			</div>
				<span class="share-icons googleplus mobile-hide"></span>
				<div class="googlehider2 mobile-hide"> 
				<div class="g-plusone mobile-hide" data-annotation="none"></div>
			</div>
				<span class="share-icons googleplus"></span>
				<span class="gp-link"><a  onclick="_gaq.push(['_trackEvent', 'Share google plus', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="#">Google+</a></span>
	</li>
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share Mandeley', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/70"><span class="share-icons mendeley"></span>Mendeley</a>
			</li>
			<li>
			<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share twitter icon', 'Article Sidebar', '/content/16/1/70', 1, true]);" href="http://twitter.com/?status=The%20gametocytocidal%20efficacy%20of%20primaquine%20in%20malaria%20asymptomatic%20carriers%20treated%20with%20dihydroartemisinin-piperaquine%20in%20The%20Gambia%20%28PRINOGAM%29%3A%20study%20protocol%20for%20a%20randomised%20controlled%20trial%20http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F70+%23trials
"><span class="share-icons twitter"></span>Twitter</a>
			</li>

			<li><a href="http://www.reddit.com/submit" onclick="window.location = 'http://www.reddit.com/submit?url=http://www.trialsjournal.com/content/16/1/70'; return false"> <span class="share-icons reddit"></span>Reddit</a>
    </li>






		</ul>
</ul>

    </div>

    
  
        
                
        


















                                                                                
	

	    
   
  
      
  
                  
  
                  
  
            
  
            
            

<div id="signup-to-etoc" class="button-collection-margins block mobile-border-bottom">	
					<h3>Email updates</h3>
			<p id="receive_issue_alerts_journal_updates_text">Keep up to date with the latest news and content from Trials and BioMed Central.</p>
			
				
<form  id="articleSignupForUpdates"  method="post" action="/signuptoupdates.html">
	<div id="message-box"></div>
    <fieldset class="block-form">
        <input type="text" name="emailAddress" onblur="javascript: if (this.value == '') { this.value = 'email address'; }" onfocus="javascript: if (this.value == 'email address') { this.value = ''; }" value="email address"  class="text " id="email" />
        <input value="" type="hidden" name="returnUrl" id="returnUrl" />
        <input value="xniche-trials" type="hidden" name="listName" id="listName" />
        <input value="Trials" type="hidden" name="journalName" id="journalName" />
        <button onclick="_gaq.push('_trackEvent', 'Signup', 'Signup for Email updates', "Trials");" class="w74 right" type="submit" onmouseover="this.className='w74 hover right'" onmouseout="this.className='w74 right'" value="Sign up">Sign up</button>
    </fieldset>
</form>	
</div>

	


			<div id="advert-offset">
    					
		<dl class="google-ad  ">
	<dt class="hide">
				
					<a class="skyscraper-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</a>
			</dt>
		<dd>

		<!-- OAS AD 'Right3' begin -->
		<script type="text/javascript">
		OAS_AD('Right3');

		</script>
		<!-- OAS AD 'Right3' end -->
		</dd>

		</dl>

		<noscript>
			<dl class="google-ad  noscript">  
    <dt class="hide"><a href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</dt>
    
    <dd>
        <a href="//oas.biomedcentral.com/RealMedia/ads/click_nx.ads/trialsjournal.com/article/10.1186/s13063/015/0597/1/18264921686@Right3?">
            <img src="//oas.biomedcentral.com/RealMedia/ads/adstream_nx.ads/trialsjournal.com/article/10.1186/s13063/015/0597/1/18366386987@Right3?" alt="advert"/>
        </a>
    </dd>
			</dl>
		</noscript>
					</div>
	

	
</div>
		<div class="mobile-sidebar-gradient top"></div>
		<div class="mobile-sidebar-gradient bottom"></div>
	</div>

</div>








 </div>
<div class="rounded custom white article full-text">
<div class="wrap-inner content">
    <div class="padded-inner">            


    
   
  
      
  
                  
  
                  
  
            
  
            
            

<div id="topmatter">
	


	   






 
  



				<a href="/about/access"><img alt="Open Access" src="/images/articles/openaccess-large.png" class="access mr15"/></a>
					<span class="articletype">Study protocol</span>

<h1>The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial</h1>
        
			<div class="multipleins">
		
	<p class="authors">
        																																																																																																																																																																																																																																																																																																																																																																         <strong>Joseph Okebe</strong><sup><a href="/content/16/1/70/#ins1">1</a></sup><sup>&#42;</sup>, <strong>Teun Bousema</strong><sup><a href="/content/16/1/70/#ins2">2</a></sup>, <strong>Muna Affara</strong><sup><a href="/content/16/1/70/#ins1">1</a></sup>, <strong>GianLuca DiTanna</strong><sup><a href="/content/16/1/70/#ins3">3</a></sup>, <strong>Alice C Eziefula</strong><sup><a href="/content/16/1/70/#ins2">2</a></sup>, <strong>Musa Jawara</strong><sup><a href="/content/16/1/70/#ins1">1</a></sup>, <strong>Davis Nwakanma</strong><sup><a href="/content/16/1/70/#ins1">1</a></sup>, <strong>Alfred Amambua-Ngwa</strong><sup><a href="/content/16/1/70/#ins1">1</a></sup>, <strong>Jean-Pierre Van geertruyden</strong><sup><a href="/content/16/1/70/#ins4">4</a></sup>, <strong>Chris Drakeley</strong><sup><a href="/content/16/1/70/#ins2">2</a></sup> and <strong>Umberto D’Alessandro</strong><sup><a href="/content/16/1/70/#ins1">1</a></sup><sup><a href="/content/16/1/70/#ins5">5</a></sup><sup><a href="/content/16/1/70/#ins6">6</a></sup>	</p>
	
				<div id="affiliations">
		<div class="module gray  inner">
<div class="module-inner padded-inner">
		<ul>
			<li>                        
                                                                                                                                                    		<p class="authors" >
							<span>*</span>
									 Corresponding author:										            Joseph  Okebe <a href='mailto:jokebe@mrc.gm'>jokebe@mrc.gm</a>    					</p>
      
</li>
			
                                                                                                                                                                                                                                                                                                                                    		</ul>

		
		 <p class="options"><a class="affiliations-toggle" href="#"><i class="arrow"></i>Author Affiliations</a></p>            <section> 
						<div class="collapsible-content">
							
				<div id="ins_container" style="display: block;">
										    						    <p >
						        <sup id="ins1">1</sup>                                Disease Control & Elimination Theme, Medical Research Council Unit, Fajara, The Gambia
                            </p>
																    						    <p >
						        <sup id="ins2">2</sup>                                Immunology and Infection Department, London School of Hygiene and Tropical Medicine, London, UK
                            </p>
																    						    <p >
						        <sup id="ins3">3</sup>                                Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population health, London School of Hygiene and Tropical Medicine, London, UK
                            </p>
																    						    <p >
						        <sup id="ins4">4</sup>                                International Health Unit, Faculty of Medicine & Health Sciences, University of Antwerp, Antwerp, Belgium
                            </p>
																    						    <p >
						        <sup id="ins5">5</sup>                                Department of Disease Control, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
                            </p>
																    						    <p >
						        <sup id="ins6">6</sup>                                Department of Public health, Institute of Tropical Medicine, Antwerp, Belgium
                            </p>
																
				</div>
										<p id="authoremails">            For all author emails, please <a href="/logon">log on</a>.
    </p>
						</div>
			</section>
				</div>
</div>
		</div>
	  </div>

            <section class="cit">
                        <div class="collapsible-content">
        <p><em>Trials</em> 2015, <strong>16</strong>:70&nbsp;
			<span class="pseudotab">doi:10.1186/s13063-015-0597-1</span></p>
	    				    
    
        
                
		<p>The electronic version of this article is the complete one and can be found online at: <a href="http://www.trialsjournal.com/content/16/1/70">http://www.trialsjournal.com/content/16/1/70</a></p>
		<br/>
                    <table cellspacing="0" cellpadding="0">
        <tbody>
        <tr><td>Received:</td><td>3 October 2014</td></tr>                <tr><td>Accepted:</td><td>10 February 2015</td></tr>        <tr><td>Published:</td><td>1 March 2015</td></tr>        </tbody>
        </table>
    		<!--<br/>-->
		<div  style="line-height:140%">
        <p>
            &copy; 2015 Okebe et al.; licensee BioMed Central. <br />
        </p>
					<p>
				This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href='http://creativecommons.org/licenses/by/4.0'>http://creativecommons.org/licenses/by/4.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
			</p>
		    	</div>
	</section>

</div>
<div id="article-body">
    <section><a name="abs"></a><h3>Abstract</h3>
   <div class="collapsible-content">
      <h4>Background</h4>
      <p style="line-height:160%">Finding efficacious tools to decrease and interrupt malaria transmission is essential
         to sustain the gains in malaria control and contain the emergence of artemisinin resistance.
         Primaquine is effective against <em>Plasmodium falciparum</em> gametocytes and recommended for treatment campaigns in (pre-)elimination settings.
         Safety concerns preclude its use in endemic African countries with variable proportions
         of glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals. The efficacy of
         the current recommended dose needs to be evaluated, particularly in individuals with
         an asymptomatic malaria infection.
      </p>
      <h4>Methods/design</h4>
      <p style="line-height:160%">This is a four-arm, open label, randomized controlled trial that aims to determine
         and compare the effect of three different single doses of primaquine combined with
         dihydroartemisinin-piperaquine, an artemisinin-based combination therapy, on gametocyte
         carriage in asymptomatic, malaria infected, G6PD-normal individuals. Approximately
         1,200 participants are enrolled and followed for 42&nbsp;days, with the primary endpoint
         being the prevalence of <em>Plasmodium falciparum</em> gametocyte carriage at day 7 of follow-up determined by quantitative nucleic acid
         sequence based amplification assay. Direct membrane feeding experiments to determine
         infectiousness to mosquitoes are conducted as a biological secondary endpoint.
      </p>
      <h4>Discussion</h4>
      <p style="line-height:160%">Sub-Saharan Africa, with a relatively high but poorly characterized G6PD prevalence,
         could potentially benefit from the use of primaquine to further reduce or interrupt
         malaria transmission. However, G6PD screening may not be feasible given the cost and
         difficulties in interpreting test results in terms of risk of haemolysis. Because
         the haemolytic effect of primaquine is dose-dependent, determining the minimal gametocytocidal
         and transmission-blocking dose of primaquine is extremely important to help address
         public health concerns over its safety and validate the efficacy of lower than recommended
         dosages. By including infectiousness to mosquitoes, the trial provides complementary
         evidence for the potential of the drug to interrupt transmission to mosquitoes.
      </p>
      <h4>Trial registration</h4>
      <p style="line-height:160%">ClinicalTrials.gov: <a href="NCT01838902">NCT01838902</a> <a href="http://www.webcitation.org/query.php?url=NCT01838902&amp;refdoi=10.1186/s13063-015-0597-1" alt="" title="Archive copy of webpage" class="xpushbutton">webcite</a> (12 April 2013).
      </p>
   </div>
</section><span id="keywords">
   <h5 class="inline">Keywords: </h5>Malaria; Plasmodium falciparum; Asymptomatic infection; Gametocyte; Primaquine; Safety; Efficacy; Elimination</span><section><a name="sec1"></a><h3>Background</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">The scale-up of anti-malaria interventions, including artemisinin-based combination
         therapy (ACT), and the subsequent decline in many malaria indicators has boosted prospects
         of local or regional malaria elimination <a name="d82585e244"></a>[<a onclick="LoadInParent('#B1'); return false;" href="#B1">1</a>]. However, it is evident that additional tools, including drugs effective against
         sexual (gametocyte) stages and programmes that are targeted at asymptomatic parasite
         carriage, would be needed if the goal of interrupting <em>Plasmodium falciparum</em> malaria transmission were to be achieved.
      </p>
      <p style="line-height:160%">A number of endemic countries, including some in sub-Saharan Africa, have achieved
         substantial reductions in their malaria burden <a name="d82585e253"></a>[<a onclick="LoadInParent('#B1'); return false;" href="#B1">1</a>],<a name="d82585e257"></a>[<a onclick="LoadInParent('#B2'); return false;" href="#B2">2</a>] and are considering the possibility of eliminating malaria within their borders.
         Artemisinin derivatives are extremely effective against both asexual and early-stage
         <em>P. falciparum</em> gametocytes and less so against mature gametocytes <a name="d82585e264"></a>[<a onclick="LoadInParent('#B3'); return false;" href="#B3">3</a>],<a name="d82585e268"></a>[<a onclick="LoadInParent('#B4'); return false;" href="#B4">4</a>]. Combining ACTs with primaquine (PQ), an 8-aminoquinoline effective against mature
         gametocytes, targets all parasite stages and thus can halt the transfer of gametocytes
         from humans to mosquitoes. In this context, PQ could play an essential role in interrupting
         transmission but there are concerns, especially over its safety and efficacy, that
         could preclude its large-scale use in these countries.
      </p>
      <p style="line-height:160%">The optimal PQ dose used in combination with an ACT against <em>P. falciparum</em> gametocytes has been the subject of some discussion. Previously recommended by the
         World Health Organization as a single 0.75&nbsp;mg base/kg, it was recently revised to
         0.25&nbsp;mg base/kg as this dose was unlikely to result in serious toxicity, especially
         in individuals with any glucose-6-phosphate dehydrogenase (G6PD) deficiency variant,
         while retaining its gametocytocidal effect <a name="d82585e277"></a>[<a onclick="LoadInParent('#B5'); return false;" href="#B5">5</a>]. Whereas the 0.75&nbsp;mg base/kg PQ dose had a variable impact on transmission <a name="d82585e281"></a>[<a onclick="LoadInParent('#B6'); return false;" href="#B6">6</a>],<a name="d82585e285"></a>[<a onclick="LoadInParent('#B7'); return false;" href="#B7">7</a>], the efficacy of the 0.25&nbsp;mg base/kg has not been evaluated in any recent trial.
      </p>
      <p style="line-height:160%">A recently concluded dose-ranging trial of PQ plus artemether-lumefantrine in children
         with uncomplicated malaria showed that a 0.4&nbsp;mg/kg dose was as efficacious as the
         0.75&nbsp;mg/kg dose in clearing gametocytes <a name="d82585e291"></a>[<a onclick="LoadInParent('#B8'); return false;" href="#B8">8</a>]. The trial excluded phenotypically G6PD-deficient individuals by fluorescent spot
         test and observed no clinically relevant haemolysis, although a statistically significant
         haemolytic effect was observed in phenotypically G6PD-sufficient but genotypically
         G6PD-deficient individuals receiving 0.75&nbsp;mg/kg or 0.4&nbsp;mg/kg PQ <a name="d82585e295"></a>[<a onclick="LoadInParent('#B9'); return false;" href="#B9">9</a>].
      </p>
      <p style="line-height:160%">The dynamics of gametocyte carriage may differ considerably between symptomatic and
         asymptomatic infections and these differences in gametocyte dynamics may explain why
         previous studies in Africa have reached different conclusions on the added value of
         PQ in symptomatic and asymptomatic infections <a name="d82585e301"></a>[<a onclick="LoadInParent('#B7'); return false;" href="#B7">7</a>],<a name="d82585e305"></a>[<a onclick="LoadInParent('#B10'); return false;" href="#B10">10</a>]. Although the acute phase of clinical malaria attacks have been associated with a
         subsequent wave of gametocytes that may persist longer after treatment <a name="d82585e309"></a>[<a onclick="LoadInParent('#B11'); return false;" href="#B11">11</a>], asymptomatic individuals typically have lower densities of both asexual and sexual
         parasites yet potentially have more mature gametocytes as a result of the long duration
         of asymptomatic parasite carriage <a name="d82585e313"></a>[<a onclick="LoadInParent('#B12'); return false;" href="#B12">12</a>]. Because asymptomatic infections typically comprise the majority of malaria infections
         in populations <a name="d82585e317"></a>[<a onclick="LoadInParent('#B13'); return false;" href="#B13">13</a>], studies in asymptomatic parasite carriers are needed to provide complementary evidence
         for the efficacy and safety of even lower PQ doses.
      </p>
      <p style="line-height:160%">This study combines gametocyte carriage measured using molecular detection methods
         <a name="d82585e323"></a>[<a onclick="LoadInParent('#B10'); return false;" href="#B10">10</a>],<a name="d82585e327"></a>[<a onclick="LoadInParent('#B14'); return false;" href="#B14">14</a>] with a complementary biological endpoint of gametocyte infectivity in a sub-group
         of study subjects to assess the transmission blocking effect of PQ <a name="d82585e331"></a>[<a onclick="LoadInParent('#B15'); return false;" href="#B15">15</a>].
      </p>
      <h4>Trial objectives and endpoints</h4>
      <p style="line-height:160%">The trial aims to determine and compare the effect of three different single doses
         of PQ combined with an ACT, dihydroartemisinin-piperaquine (DHA-PPQ), on gametocyte
         carriage in asymptomatic, malaria-infected, G6PD-normal individuals. In addition,
         it will determine and compare the effect of the above combinations on change in haemoglobin
         concentration during follow-up, infectiousness to mosquitoes, parasite clearance time
         and cure rate.
      </p>
      <p style="line-height:160%">The main trial endpoint is the prevalence of <em>P. falciparum</em> gametocyte carriage at day 7 of follow-up determined by quantitative nucleic acid
         sequence based amplification assay (QT-NASBA).
      </p>
      <p style="line-height:160%">Other endpoints include: 1) the prevalence of <em>P. falciparum</em> gametocyte carriage, determined by QT-NASBA, during other follow-up visits; 2) change
         in haemoglobin values between enrollment (day 0) and each day of follow-up; 3) infectiousness
         to mosquitoes on day 7 determined by direct membrane feeding assay (DMFA); 4) proportion
         of participants with recurrent infections (polymerase chain reaction adjusted and
         unadjusted) after day 7; and 5) the prevalence of adverse events and serious adverse
         events.
      </p>
   </div>
</section>
<section><a name="sec2"></a><h3>Methods</h3>
   <div class="collapsible-content">
      <h4>Design</h4>
      <p style="line-height:160%">This is a four-arm, open label, randomized controlled trial in which G6PD-normal asymptomatic
         <em>Plasmodium falciparum</em>-infected individuals identified through population screening are randomized to receive
         either a complete course of DHA-PPQ alone (control) or a course of DHA-PPQ plus one
         of three different doses of PQ (intervention): 0.75&nbsp;mg base/kg, 0.4&nbsp;mg base/kg and
         0.2&nbsp;mg base/kg, given as a single dose.
      </p>
      <h4>Study area and participant selection</h4>
      <p style="line-height:160%">Participants are recruited from villages around the Medical Research Council’s field
         stations in the Central and Upper River Regions in The Gambia. Malaria transmission
         in the country is well described, and characterized by marked seasonality with a peak
         between September and November <a name="d82585e370"></a>[<a onclick="LoadInParent('#B16'); return false;" href="#B16">16</a>]. Participants are selected in a two-stage screening process. An initial pre-screening
         is used to determine infection (rapid antigen test kit) and establish a baseline parasitaemia
         (microscopy). Individuals aged 1&nbsp;year and above with parasite density ≥20 parasites/μl
         are invited to the base clinic the following day where, after a written informed consent,
         they undergo screening for G6PD status (N Dimopoulos SA, Greece), haemoglobin measurement
         (Hemocue, Ängelholm, Sweden) and, if eligible, are enrolled (Figure&nbsp;<a name="d82585e373"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/70/figure/F1','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/70/figure/F1">1</a>). Infected but ineligible persons are treated with a full course of artemether-lumefantrine.
         In addition, those with haemoglobin counts &lt;8&nbsp;g/dl receive iron supplements while
         G6PD-deficient individuals will be counselled on their test results and provided with
         a notification card indicating their G6PD status which they are advised to present
         at clinics when seeking medical care.
         
      </p><div class="figs">
      <div class="fig"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/70/figure/F1','F1',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/70/figure/F1"><img align="top" src="/content/figures/s13063-015-0597-1-1.gif" alt="thumbnail" class="thumbnail"><strong>Figure 1.</strong></a> <strong>DHA-PPQ, dihydroartemisinin-piperaquine; DMFA, direct membrane feeding assay; Hb,
            haemoglobin; G6PD, glucose-6-phosphate dehydrogenase; PCR, polymerase chain reaction;
            PQ, primaquine; RDT, rapid diagnostic test.</strong></div></div>
      <h4>Randomisation and blinding</h4>
      <p style="line-height:160%">Enrolment into the trial arms follows a randomisation scheme in a 1:1:1:1 ratio using
         blocks of varying size to ensure a balance in recruitment between the four groups.
         A randomisation list, generated by the trial statistician using Stata software version
         13 (Stata Corp. College Station, TX, USA), is sent to a physician not involved in
         the trial who puts the codes for the allocation groups into sequentially numbered,
         opaque envelopes. The envelopes are opened by the clinic team only after the potential
         participant meets the eligibility criteria.
      </p>
      <p style="line-height:160%">This is an open-label trial; staff involved in clinical care, including administering
         the trial drugs, are aware of the assigned groups but those involved in sample processing
         and data analysis are blinded.
      </p>
      <h4>Treatment and follow-up</h4>
      <p style="line-height:160%">All participants in the trial will receive a complete 3-day course of DHA-PPQ based
         on body weight according to the manufacturer’s instructions. DHA-PPQ is available
         as both paediatric (dihydroartemisinin 20&nbsp;mg/piperaquine 160&nbsp;mg) and adult (dihydroartemisinin
         40&nbsp;mg/piperaquine 320&nbsp;mg) formulations. Participants in the three intervention arms
         are randomized to receive a single 0.75&nbsp;mg/kg, 0.40&nbsp;mg/kg or 0.20&nbsp;mg/kg dose of PQ
         base on day 2 with the third dose of DHA-PPQ. Each tablet of PQ contains 15&nbsp;mg base
         and, to ensure the accuracy of doses &lt;15&nbsp;mg, the tablet will be reconstituted in 15&nbsp;ml
         water to achieve a 1&nbsp;mg/ml concentration and the required dose dispensed using a sterile
         syringe. A nurse directly observes all treatments and treatment may be repeated once
         if a participant vomits any of the drugs within 30&nbsp;minutes of being administered.
      </p>
      <p style="line-height:160%">Each participant attends eight scheduled follow-up visits on days 3, 7, 10, 14, 21,
         28, 35, and 42 for clinical evaluation and blood sampling. Blood samples from a finger
         prick are collected for gametocyte (QT-NASBA) and asexual parasite clearance (microscopy
         and polymerase chain reaction) and haemoglobin measurement. Additional tests may be
         requested during unscheduled visits to the clinic (Table&nbsp;<a name="d82585e404"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/70/table/T1','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/70/table/T1">1</a>). Thick blood films stained with 10% Giemsa for 10&nbsp;minutes are examined under 1000-fold
         magnification by trained microscopists. Asexual parasite density is determined by
         counting the number of asexual parasites per white blood cell (WBC) until 500 WBCs
         have been counted (assuming a mean WBC count of 8,000/μl) and results presented as
         parasites/μl.
         
      </p><div class="figs">
      <div class="table"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/70/table/T1','T1',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/70/table/T1"><strong>Table 1.</strong></a> <strong>Trial activity on scheduled visit days</strong></div></div>
      <h4>Quantitative nucleic acid sequence based amplification assay</h4>
      <p style="line-height:160%">The primary endpoint of the trial is the prevalence of gametocytes measured by molecular
         methods on day 7 of follow-up. The detection and quantification of gametocytes is
         by real-time QT-NASBA which is based on stage-specific gene expression of Pfs25 mRNA
         by parasites. QT-NASBA is a high throughput technique suited to detecting mature gametocytes
         with a sensitivity of 0.01 to 0.1 gametocytes/μl blood <a name="d82585e831"></a>[<a onclick="LoadInParent('#B17'); return false;" href="#B17">17</a>]. It is based on the activities of three enzymes: Reverse transcriptase, T7 RNA polymerase
         and RNase H and target-specific forward and reverse primers, which includes a T7 polymerase
         promoter sequence, for continuous and direct amplification of RNA molecules in a single
         mixture at an isothermal temperature of 41°C. Real-time gametocyte detection and quantification
         is by a fluorescent-labelled molecular beacon with a sequence complementary to those
         of amplified anti-sense RNA molecules.
      </p>
      <p style="line-height:160%">RNA is extracted manually from 50&nbsp;μl of blood stored in RNAlater using commercial
         lysis buffers (Severn Biotech, Kidderminster, Worcestershire, UK) and previously described
         methods that involve nuclease inactivation and nucleic acid binding <a name="d82585e837"></a>[<a onclick="LoadInParent('#B18'); return false;" href="#B18">18</a>]. Gametocyte density is calculated in relation to the standard gametocyte stage V
         dilution series using the time point of amplification at which the fluorescence detecting
         target amplicons exceed the mean fluorescence of three negative controls + 20 standard
         deviations <a name="d82585e841"></a>[<a onclick="LoadInParent('#B17'); return false;" href="#B17">17</a>]. Standard curves for density quantification are generated using trend lines of known
         quantities of gametocytes from laboratory-cultured NF54 parasite strains.
      </p>
      <h4>Direct membrane feeding assay</h4>
      <p style="line-height:160%">To measure biological evidence of gametocyte clearance, a subset of 100 participants
         from each arm will be randomly selected for direct membrane feeding experiments on
         day 7 using a published protocol <a name="d82585e851"></a>[<a onclick="LoadInParent('#B19'); return false;" href="#B19">19</a>]. In summary, 3&nbsp;ml of blood are collected from the participant’s arm and 500&nbsp;μl is
         added to two glass feeders and fed to about 100 locally reared 4- to 5-day-old female
         <em>Anopheles gambiae sensu stricto</em> mosquitoes through an artificial membrane. The setup is maintained at 37°C by a temperature
         controlled water bath and, after 15&nbsp;minutes of feeding, fully fed mosquitoes are transferred
         into a holding cage maintained at 27 to 29°C and sustained on 5% glucose for 7&nbsp;days
         while partially fed and unfed ones are destroyed. Mosquitoes that survive to this
         period are dissected in 0.5% mercurochrome, and their midguts examined for oocyst
         prevalence and density. The proportion of infected mosquitoes, the number of infected
         mosquitoes divided by the total number of examined mosquitoes, and the density of
         oocysts in infected mosquitoes is presented.
      </p>
      <h4>Sample size considerations</h4>
      <p style="line-height:160%">The sample size was calculated to detect a difference in gametocyte prevalence on
         day 7 after treatment, between the control (DHA-PPQ only) and 0.75&nbsp;mg/kg PQ arm, and
         between this and lower doses of PQ (0.4&nbsp;mg/kg and 0.2&nbsp;mg/kg). Two hypotheses underscore
         the sample size calculation: 1) treatment with PQ (any dose) and DHA-PPQ results in
         significantly lower gametocyte carriage compared to treatment with DHA-PPQ alone;
         and 2) a single dose of 0.4&nbsp;mg base/kg or 0.2&nbsp;mg base/kg PQ administered with the
         last dose of DHA-PPQ has similar gametocytocidal efficacy as a single 0.75&nbsp;mg base/kg
         dose.
      </p>
      <p style="line-height:160%">For the first hypothesis, the underlying assumption is that, although a substantial
         proportion of asymptomatic carriers also carry gametocytes <a name="d82585e866"></a>[<a onclick="LoadInParent('#B20'); return false;" href="#B20">20</a>], treatment with an ACT alone would reduce gametocyte prevalence on day 7 to around
         18%, and the addition of PQ at 0.75&nbsp;mg/kg will further reduce the prevalence by 50%
         (that is, to 9%). A sample size of 300 participants per arm would have 90% power to
         detect this difference, at the 5% significance level, allowing for 10% of enrolees
         being non-compliant or lost to follow-up.
      </p>
      <p style="line-height:160%">In the second hypothesis, assuming a prevalence of 9% in the standard PQ arm, 300
         participants would be sufficient, with 90% power, to detect a confidence interval
         around the prevalence in the lower dose PQ arm below 16% and 80% power to detect that
         this confidence interval is entirely below 15%.
      </p>
      <h4>Statistical analysis plan</h4>
      <p style="line-height:160%">Analysis of efficacy will be on the basis of intention-to-treat. Gametocyte densities
         will be compared between treatment groups using one-way analysis of variance on log-transformed
         gametocyte densities; gametocyte carriage during follow-up will be estimated by calculating
         for each arm the area under the curve (AUC) of both the gametocyte density and gametocyte
         prevalence against time. The AUC between treatment groups will be compared using non-parametric
         tests. The Kaplan-Meier estimator will be used to compare gametocyte clearance times
         between study arms for individuals who are gametocyte positive by QT-NASBA at enrolment.
      </p>
      <p style="line-height:160%">For the non-inferiority comparison between the PQ arms, the 95% confidence around
         the gametocyte prevalence in the PQ 0.4/0.2&nbsp;mg/kg arms at day 7 will be compared to
         the non-inferiority limit determined by the prevalence in the PQ 0.75&nbsp;mg/kg arm and
         delta.
      </p>
      <p style="line-height:160%">For the DMFA, the proportion of infectious individuals will be compared between arms
         using chi-squared statistics. The proportion of infected mosquitoes will be compared
         between groups using mixed models to account for clustering within cages fed on blood
         from the same individual.
      </p>
      <h4>Data entry and validation</h4>
      <p style="line-height:160%">Clinical data will be captured from pre-tested medical records and relevant fields
         entered onto an electronic case report form base created in Openclinica (OpenClinica
         LLC, Waltham, Ma, USA). Data will be single entered with source-data verification
         done for each entry. Laboratory-generated (DMFA and QT-NASBA) data will be double
         entered onto a Microsoft Access database (Microsoft Corp., Richmond, WA, USA) and
         linked to the clinical data after validation.
      </p>
      <h4>Ethical approval</h4>
      <p style="line-height:160%">The trial was approved by The Gambia Government/MRC Joint Ethics Committee (SCC 1321)
         on 13 March 2013.
      </p>
   </div>
</section>
<section><a name="sec3"></a><h3>Discussion</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">Local and regional malaria elimination is gaining acceptance as a means to sustain
         the gains made in reducing the malaria burden and limiting/preventing the spread of
         artemisinin resistance. However, achieving these objectives would require a fresh
         perspective on the necessary tools and applications.
      </p>
      <p style="line-height:160%">Although individuals with clinical disease due to asexual <em>P. falciparum</em> infection also carry gametocytes in variable amounts <a name="d82585e905"></a>[<a onclick="LoadInParent('#B21'); return false;" href="#B21">21</a>], asymptomatic infections are believed to play an important role across all levels
         of malaria transmission and therefore targeting only clinical cases would miss the
         large human reservoir of infection <a name="d82585e909"></a>[<a onclick="LoadInParent('#B12'); return false;" href="#B12">12</a>]. This concept is supported by evidence from empirical studies and mathematical models
         <a name="d82585e913"></a>[<a onclick="LoadInParent('#B22'); return false;" href="#B22">22</a>],<a name="d82585e917"></a>[<a onclick="LoadInParent('#B23'); return false;" href="#B23">23</a>], and the combination of an ACT with PQ is recommended in places where (pre-)elimination
         is being considered <a name="d82585e922"></a>[<a onclick="LoadInParent('#B24'); return false;" href="#B24">24</a>].
      </p>
      <p style="line-height:160%">In asymptomatic infections, parasite density (both asexual forms and gametocytes)
         are much lower than in clinical cases. However, one model estimate predicts that these
         low-density infections, even when undetectable by microscopy, may still be infectious
         to mosquitoes <a name="d82585e928"></a>[<a onclick="LoadInParent('#B25'); return false;" href="#B25">25</a>]. Parasite densities are estimated by counting parasites against a given number of
         WBCs, usually 200 WBCs, and then assuming 8,000 WBCs per μl <a name="d82585e932"></a>[<a onclick="LoadInParent('#B26'); return false;" href="#B26">26</a>]. Nevertheless, when parasite densities are &lt;100/μl, a higher sensitivity may be needed
         <a name="d82585e936"></a>[<a onclick="LoadInParent('#B26'); return false;" href="#B26">26</a>] and this can be done by increasing the number of WBCs against which the number of
         parasites are counted, usually 500. Given the short time available to recruit participants
         into the trial, counting parasites against 500 WBCs is extremely challenging.
      </p>
      <p style="line-height:160%">As the trial aims to determine the lowest gametocytocidal PQ dose, it was necessary
         to include individuals with microscopically detectable infections. The threshold of
         &gt;20 parasites/μl as an inclusion criterion was chosen as a proxy to increase the likelihood
         for gametocytaemia <a name="d82585e942"></a>[<a onclick="LoadInParent('#B11'); return false;" href="#B11">11</a>]. Including carriers of submicroscopic infection would not have been feasible given
         the need to determine their eligibility in a relatively short time. Blood slides can
         be re-read later and the number of WBCs per slide increased for higher sensitivity
         <a name="d82585e946"></a>[<a onclick="LoadInParent('#B27'); return false;" href="#B27">27</a>].
      </p>
      <p style="line-height:160%">The potential for inducing haemolysis is probably the main reservation for the widespread
         use of PQ. In sub-Saharan Africa, the overall prevalence of G6PD deficiency is considered
         to be high <a name="d82585e952"></a>[<a onclick="LoadInParent('#B28'); return false;" href="#B28">28</a>]. A recent survey in The Gambia showed that the prevalence of the 202A- mutation,
         reportedly the most common in sub-Saharan Africa, was 1.8% while the phenotype prevalence
         was 6.4% overall; 7.8% in males and 4.9% in females <a name="d82585e956"></a>[<a onclick="LoadInParent('#B29'); return false;" href="#B29">29</a>]. Such low numbers may suggest a low risk but does not eliminate it entirely as individuals
         with “normal” G6PD status have developed haemolysis <a name="d82585e960"></a>[<a onclick="LoadInParent('#B30'); return false;" href="#B30">30</a>]. A trial to evaluate the tolerability and safety of increasing doses of PQ in combination
         with an ACT in G6PD-deficient males with an asymptomatic <em>P. falciparum</em> malaria infection has recently been initiated (NCT02174900) and the results would
         complement those of this trial.
      </p>
      <p style="line-height:160%">As the haemolytic effect of PQ is dose-dependent, determining the minimal gametocytocidal
         dose is considered an extremely important first step in addressing public health concerns
         related to the safety and efficacy of PQ as summarized in a recent systematic review
         <a name="d82585e969"></a>[<a onclick="LoadInParent('#B31'); return false;" href="#B31">31</a>]. Since the initial trial protocol was developed, a single 0.25&nbsp;mg base/kg dose of
         PQ combined with an ACT is now recommended as sufficiently safe and gametocytocidal
         to be used without screening for G6PD deficiency <a name="d82585e973"></a>[<a onclick="LoadInParent('#B5'); return false;" href="#B5">5</a>]. However, the evidence for this dose may be considered inadequate by contemporary
         standards.
      </p>
      <p style="line-height:160%">The optimization of the PQ dosing regimen therefore represents an important knowledge
         gap and research priority <a name="d82585e979"></a>[<a onclick="LoadInParent('#B32'); return false;" href="#B32">32</a>] as it provides a “new/old” tool for malaria (pre-)elimination. The recently concluded
         dose-finding trial in children aged 1 to 10&nbsp;years with uncomplicated falciparum malaria
         and normal G6PD enzyme function provides encouraging complementary information to
         support research in G6PD-deficient individuals <a name="d82585e983"></a>[<a onclick="LoadInParent('#B8'); return false;" href="#B8">8</a>]. Also, the haematological consequences may be less manifest in asymptomatic carriers
         as the malaria-related haemolysis would be less pronounced.
      </p>
      <p style="line-height:160%">By evaluating infectiousness to mosquitoes, the trial contributes a biological endpoint
         - the evidence for transmission reduction or complete transmission blockade to mosquitoes
         that is ultimately relevant for public health policy making.
      </p>
   </div>
</section>
<section><a name="sec4"></a><h3>Trial status</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">Recruitment started in August 2013 with trial results expected in December 2015.</p>
   </div>
</section>
<section><a name="sec5"></a><h3>Abbreviations</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">ACT: artemisinin-based combination therapy</p>
      <p style="line-height:160%">AUC: area under the curve</p>
      <p style="line-height:160%">DHA-PPQ: dihydroartemisinin-piperaquine</p>
      <p style="line-height:160%">DMFA: direct membrane feeding assay</p>
      <p style="line-height:160%">G6PD: glucose-6-phosphate dehydrogenase</p>
      <p style="line-height:160%">PQ: primaquine</p>
      <p style="line-height:160%">QT-NASBA: quantitative nucleic acid sequence based amplification assay</p>
      <p style="line-height:160%">WBC: white blood cell</p>
   </div>
</section>
<section><a name="sec6"></a><h3>Competing interests</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">The authors declare that they have no competing interests.</p>
   </div>
</section>
<section><a name="sec7"></a><h3>Authors’ contributions</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">UDA conceived the study and wrote the trial protocol. JO contributed to the protocol
         design, wrote the draft manuscript and coordinated the trial activities. CD and TB
         developed the protocol for membrane feeding and contributed to the trial protocol
         design. TB, MA, AAN and DN developed and tested the protocols for laboratory assays
         used in the trial. GLDT wrote the statistical analysis plan and reviewed the sample
         size calculations. ACE contributed to the design of the trial. MJ contributed to developing
         the membrane feeding protocol. UDA and JPVG contributed to the writing and review
         of the manuscript. All authors read and reviewed the manuscript, and approved the
         final manuscript.
      </p>
   </div>
</section>
<section><a name="ack"></a><h3>Acknowledgements</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">The authors acknowledge Mathurin Diatta and Abdoulaye Gaye for setting up the membrane
         feeding experiments, Drs Edgard Dabira and Frank Sanya-Isijola for drafting the standard
         operating procedures and supervising the field teams, and Henry Badji for supervising
         laboratory activities. CD and TB are supported by a grant from the Bill &amp; Melinda
         Gates Foundation (AFIRM, grant number OPP1034789). The trial is jointly funded under
         the Global Health Trials Scheme by the Medical Research Council (UK), the Department
         for International Development (DFID) and the Wellcome Trust. The funders have no role
         in the trial design or the preparation of the protocol or manuscript.
      </p>
   </div>
</section>
<section><a name="refs"></a><h3>References</h3>
   <div id="article-references" class="collapsible-content">
      <ol id="references">
         <li id="B1">
            <p><a name="B1"></a> O’Meara WP,  Mangeni JN,  Steketee R,  Greenwood B: <strong> Changes in the burden of malaria in sub-Saharan Africa. </strong><p><em>Lancet Infect Dis</em> 2010,  <strong>10</strong><strong>:</strong>545-55.  <a target="_blank" href="/pubmed/20637696">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=20637696">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B1" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B1','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B2">
            <p><a name="B2"></a> Ceesay SJ,  Casals-Pascual C,  Nwakanma DC,  Walther M,  Gomez-Escobar N,  Fulford AJ, <em>et al</em>.: <strong> Continued decline of malaria in The Gambia with implications for elimination. </strong><p><em>PLoS One</em> 2010,  <strong>5</strong><strong>:</strong>e12242.  <a target="_blank" href="/pubmed/20805878">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=20805878">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B2" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B2','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B3">
            <p><a name="B3"></a>malERA Consultative Group on Drugs: 
               	<strong> A research agenda for malaria eradication: drugs </strong><p><em>PLoS Med</em> 2011,  <strong>8</strong><strong>:</strong>e1000402.   <a target="_blank" href="http://dx.doi.org/10.1371/journal.pmed.1000402">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B3" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B3','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B4">
            <p><a name="B4"></a> Gosling RD,  Okell L,  Mosha J,  Chandramohan D: <strong> The role of antimalarial treatment in the elimination of malaria. </strong><p><em>Clin Microbiol Infect</em> 2011,  <strong>17</strong><strong>:</strong>1617-23.  <a target="_blank" href="/pubmed/21951597">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=21951597">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B4" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B4','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B5">
            <p><a name="B5"></a> White N,  Qiao L,  Qi G,  Luzzatto L: <strong> Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide
                  in populations where G6PD deficiency is common. </strong><p><em>Malar J</em> 2012,  <strong>11</strong><strong>:</strong>418.  <a target="_blank" href="/pubmed/23237606">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://dx.doi.org/10.1186/1475-2875-11-418">BioMed&nbsp;Central&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B5" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B5','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B6">
            <p><a name="B6"></a> Shekalaghe SA,  Drakeley C,  van den Bosch S,  ter Braak R,  van den Bijllaardt W,  Mwanziva C, <em>et al</em>.: <strong> A cluster-randomized trial of mass drug administration with a gametocytocidal drug
                  combination to interrupt malaria transmission in a low endemic area in Tanzania. </strong><p><em>Malar J</em> 2011,  <strong>10</strong><strong>:</strong>247.  <a target="_blank" href="/pubmed/21864343">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://dx.doi.org/10.1186/1475-2875-10-247">BioMed&nbsp;Central&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B6" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B6','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B7">
            <p><a name="B7"></a> El-Sayed B,  El-Zaki SE,  Babiker H,  Gadalla N,  Ageep T,  Mansour F, <em>et al</em>.: <strong> A randomized open-label trial of artesunate-sulfadoxine-pyrimethamine with or without
                  primaquine for elimination of sub-microscopic P falciparum parasitaemia and gametocyte
                  carriage in eastern Sudan. </strong><p><em>PLoS One</em> 2007,  <strong>2</strong><strong>:</strong>e1311.  <a target="_blank" href="/pubmed/18074034">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=18074034">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B7" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B7','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B8">
            <p><a name="B8"></a> Eziefula AC,  Bousema T,  Yeung S,  Kamya M,  Owaraganise A,  Gabagaya G, <em>et al</em>.: <strong> Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children
                  with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging
                  trial. </strong><p><em>Lancet Infect Dis</em> 2014,  <strong>14</strong><strong>:</strong>130-9.  <a target="_blank" href="/pubmed/24239324">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=24239324">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B8" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B8','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B9">
            <p><a name="B9"></a> Eziefula AC,  Pett H,  Grignard L,  Opus S,  Kiggundu M,  Kamya MR, <em>et al</em>.: <strong> Glucose-6-phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum-infected
                  African children receiving single-dose primaquine. </strong><p><em>Antimicrob Agents Chemother</em> 2014,  <strong>58</strong><strong>:</strong>4971-3.  <a target="_blank" href="/pubmed/24913169">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=24913169">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B9" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B9','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B10">
            <p><a name="B10"></a> Shekalaghe S,  Drakeley C,  Gosling R,  Ndaro A,  van Meegeren M,  Enevold A, <em>et al</em>.: <strong> Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after
                  treatment with sulphadoxine-pyrimethamine and artesunate. </strong><p><em>PLoS One</em> 2007,  <strong>2</strong><strong>:</strong>e1023.  <a target="_blank" href="/pubmed/17925871">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=17925871">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B10" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B10','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B11">
            <p><a name="B11"></a> Dunyo S,  Milligan P,  Edwards T,  Sutherland C,  Targett G,  Pinder M: <strong> Gametocytaemia after drug treatment of asymptomatic plasmodium falciparum. </strong><p><em>PLoS Clin Trials</em> 2006,  <strong>1</strong><strong>:</strong>20.   <a target="_blank" href="http://dx.doi.org/10.1371/journal.pctr.0010020">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B11" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B11','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B12">
            <p><a name="B12"></a> Drakeley CJ,  Akim NI,  Sauerwein RW,  Greenwood BM,  Targett GA: <strong> Estimates of the infectious reservoir of Plasmodium falciparum malaria in The Gambia
                  and in Tanzania. </strong><p><em>Trans R Soc Trop Med Hyg</em> 2000,  <strong>94</strong><strong>:</strong>472-6.  <a target="_blank" href="/pubmed/11132369">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=11132369">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B12" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B12','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B13">
            <p><a name="B13"></a> Lindblade KA,  Steinhardt L,  Samuels A,  Kachur SP,  Slutsker L: <strong> The silent threat: asymptomatic parasitemia and malaria transmission. </strong><p><em>Expert Rev Anti Infect Ther</em> 2013,  <strong>11</strong><strong>:</strong>623-39.  <a target="_blank" href="/pubmed/23750733">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=23750733">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B13" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B13','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B14">
            <p><a name="B14"></a> Kast K,  Berens-Riha N,  Zeynudin A,  Abduselam N,  Eshetu T,  Loscher T, <em>et al</em>.: <strong> Evaluation of Plasmodium falciparum gametocyte detection in different patient material. </strong><p><em>Malar J</em> 2013,  <strong>12</strong><strong>:</strong>438.  <a target="_blank" href="/pubmed/24305630">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://dx.doi.org/10.1186/1475-2875-12-438">BioMed&nbsp;Central&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B14" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B14','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B15">
            <p><a name="B15"></a> White N: <strong> The role of anti-malarial drugs in eliminating malaria. </strong><p><em>Malar J</em> 2008,  <strong>7</strong><strong>:</strong>S8.  <a target="_blank" href="/pubmed/19091042">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://dx.doi.org/10.1186/1475-2875-7-S1-S8">BioMed&nbsp;Central&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B15" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B15','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B16">
            <p><a name="B16"></a> Ceesay SJ,  Casals-Pascual C,  Erskine J,  Anya SE,  Duah NO,  Fulford AJ, <em>et al</em>.: <strong> Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. </strong><p><em>Lancet</em> 2008,  <strong>372</strong><strong>:</strong>1545-54.  <a target="_blank" href="/pubmed/18984187">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=18984187">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B16" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B16','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B17">
            <p><a name="B17"></a> Pinder M,  Jawara M,  Jarju LB,  Kandeh B,  Jeffries D,  Lluberas MF, <em>et al</em>.: <strong> To assess whether indoor residual spraying can provide additional protection against
                  clinical malaria over current best practice of long-lasting insecticidal mosquito
                  nets in The Gambia: study protocol for a two-armed cluster-randomised trial. </strong><p><em>Trials</em> 2011,  <strong>12</strong><strong>:</strong>147.  <a target="_blank" href="/pubmed/21663656">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://dx.doi.org/10.1186/1745-6215-12-147">BioMed&nbsp;Central&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B17" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B17','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B18">
            <p><a name="B18"></a> Drakeley CJ,  Flobbe K,  Greenwood BM,  Targett GA: <strong> Plasmodium falciparum gametocytes in Gambian adults. </strong><p><em>Ann Trop Med Parasitol</em> 2000,  <strong>94</strong><strong>:</strong>399-401.  <a target="_blank" href="/pubmed/10945050">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=10945050">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B18" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B18','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B19">
            <p><a name="B19"></a>Ouédraogo AL, Guelbéogo WM, Cohuet A, Morlais I, King JG, Gonçalves BP, et al. Methodology:
               a protocol for membrane feeding assays to determine the infectiousness of P. falciparum
               naturally infected individuals to Anopheles gambiae. Malaria World J. 2013;4.
            </p>
         </li>
         <li id="B20">
            <p><a name="B20"></a> Ouedraogo AL,  Schneider P,  de Kruijf M,  Nebie I,  Verhave JP,  Cuzin-Ouattara N, <em>et al</em>.: <strong> Age-dependent distribution of Plasmodium falciparum gametocytes quantified by Pfs25
                  real-time QT-NASBA in a cross-sectional study in Burkina Faso. </strong><p><em>Am J Trop Med Hyg</em> 2007,  <strong>76</strong><strong>:</strong>626-30.  <a target="_blank" href="/pubmed/17426160">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=17426160">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B20" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B20','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B21">
            <p><a name="B21"></a> Bousema T,  Okell L,  Shekalaghe S,  Griffin JT,  Omar S,  Sawa P, <em>et al</em>.: <strong> Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection
                  methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal
                  drugs. </strong><p><em>Malar J</em> 2010,  <strong>9</strong><strong>:</strong>136.  <a target="_blank" href="/pubmed/20497536">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://dx.doi.org/10.1186/1475-2875-9-136">BioMed&nbsp;Central&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B21" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B21','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B22">
            <p><a name="B22"></a> Song J,  Socheat D,  Tan B,  Dara P,  Deng C,  Sokunthea S, <em>et al</em>.: <strong> Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine. </strong><p><em>Malar J</em> 2010,  <strong>9</strong><strong>:</strong>57.  <a target="_blank" href="/pubmed/20175930">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://dx.doi.org/10.1186/1475-2875-9-57">BioMed&nbsp;Central&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B22" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B22','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B23">
            <p><a name="B23"></a> Lawpoolsri S,  Klein EY,  Singhasivanon P,  Yimsamran S,  Thanyavanich N,  Maneeboonyang W, <em>et al</em>.: <strong> Optimally timing primaquine treatment to reduce Plasmodium falciparum transmission
                  in low endemicity Thai-Myanmar border populations. </strong><p><em>Malar J</em> 2009,  <strong>8</strong><strong>:</strong>159.  <a target="_blank" href="/pubmed/19604346">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://dx.doi.org/10.1186/1475-2875-8-159">BioMed&nbsp;Central&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B23" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B23','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B24">
            <p><a name="B24"></a>World Health Organization: 
               	<em>Guidelines for the Treatment of Malaria</em>.  2nd edition.  World Health Organization, Geneva;  2010. <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B24" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B24','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B25">
            <p><a name="B25"></a> Churcher TS,  Bousema T,  Walker M,  Drakeley C,  Schneider P,  Ouédraogo AL, <em>et al</em>.: <strong> Predicting mosquito infection from Plasmodium falciparum gametocyte density and estimating
                  the reservoir of infection. </strong><p><em>eLife</em> 2013,  <strong>2</strong><strong>:</strong>e00626.  <a target="_blank" href="/pubmed/23705071">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=23705071">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B25" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B25','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B26">
            <p><a name="B26"></a>World Health Organization: 
               	<em>Malaria Microscopy Quality Assurance Manual, vol. 1</em>.  World Health Organization, Geneva;  2008. <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B26" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B26','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B27">
            <p><a name="B27"></a> Bousema T,  Okell L,  Felger I,  Drakeley C: <strong> Asymptomatic malaria infections: detectability, transmissibility and public health
                  relevance. </strong><p><em>Nat Rev Microbiol</em> 2014,  <strong>12</strong><strong>:</strong>833-40.  <a target="_blank" href="/pubmed/25329408">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=25329408">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B27" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B27','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B28">
            <p><a name="B28"></a> Howes RE,  Piel FB,  Patil AP,  Nyangiri OA,  Gething PW,  Dewi M, <em>et al</em>.: <strong> G6PD deficiency prevalence and estimates of affected populations in malaria endemic
                  countries: a geostatistical model-based map. </strong><p><em>PLoS Med</em> 2012,  <strong>9</strong><strong>:</strong>e1001339.  <a target="_blank" href="/pubmed/23152723">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=23152723">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B28" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B28','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B29">
            <p><a name="B29"></a> Okebe J,  Amambua-Ngwa A,  Parr J,  Nishimura S,  Daswani M,  Takem EN, <em>et al</em>.: <strong> The prevalence of glucose-6-phosphate dehydrogenase deficiency in Gambian school children. </strong><p><em>Malar J</em> 2014,  <strong>13</strong><strong>:</strong>148.  <a target="_blank" href="/pubmed/24742291">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://dx.doi.org/10.1186/1475-2875-13-148">BioMed&nbsp;Central&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B29" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B29','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B30">
            <p><a name="B30"></a> Shekalaghe SA,  ter Braak R,  Daou M,  Kavishe R,  van den Bijllaardt W,  van den Bosch S, <em>et al</em>.: <strong> In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin
                  is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. </strong><p><em>Antimicrob Agents Chemother</em> 2010,  <strong>54</strong><strong>:</strong>1762-8.  <a target="_blank" href="/pubmed/20194698">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=20194698">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B30" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B30','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B31">
            <p><a name="B31"></a> Graves PM,  Gelband H,  Garner P: <strong> Primaquine for reducing Plasmodium falciparum transmission. </strong><p><em>Cochrane Database Syst Rev</em> 2012.,  <strong>9</strong><p>Article ID CD008152</p> <a target="_blank" href="/pubmed/22972117">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=22972117">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0597-1&amp;bibl=B31" onclick="popup('/sfx_links?ui=s13063-015-0597-1&amp;bibl=B31','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B32">
            <p><a name="B32"></a>A research agenda for malaria eradication: drugs. PLoS Med. 2011;8:e1000402.
            </p>
         </li>
      </ol>
   </div>
</section>
    <br class="clearall">
<div class="article-alert-signup-div">

<a class="close png_bg" id="closeHelpBox" >close</a>	
<div class="article-alert-signup rounded" > 
<span class="blurb left">Sign up to receive new article alerts from <em>Trials</em></span>

	
				<button name="articleAlertPreference.status" type="button" class="w74 right" onClick="window.location='/my/preferences'">Sign up</button>
	
</div>
</div></div>
    </div></div>
</div>


		</div>
</div>

    <hr class="hide" />
	
    

						
   
  
      
  
                  
  
                  
  
            
  
            
            


<div id="footer">

						
			<span class="views"><a id="mobile-view" href="?fmt_view=mobile">Mobile view</a> | <strong>Desktop view</strong></span>
			
	<div class="content">
    <div class="rounded ">
<div class="wrap-inner ">
        	
    <ul class="desktop">
                                                    
				        <li class="noborder"><a href="http://www.biomedcentral.com/about/tandc">Terms and Conditions</a></li>
<li><a href="http://www.biomedcentral.com/about/privacy">Privacy statement</a></li>
<li><a href="http://www.biomedcentral.com/presscenter">Press</a></li>
	<li><a href="http://www.biomedcentral.com/advertisers">Information for advertisers</a></li>
<li><a href="http://www.biomedcentral.com/about/bmcjobs">Jobs at BMC</a></li>
<li><a href="/support">Support</a></li>
<li><a href="/about/contact">Contact us</a></li>


    
    	    </ul>
    <p id="copyright">&copy; 2015 
	BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business&nbsp;Media.</p>
        </div>
</div>

	</div>

</div>
<div class="springer">
    <a href="http://www.springer.com/" target="blank"><img style="float:right; margin:0;" src="
    //www.biomedcentral.com/images/Springer_Branding_footer_logo.png" /></a>
</div>


<script>window.bmcIsMobile = "classic";</script>					    

<script>
// getElementsByClassName Polyfill
var getElementsByClassName=function(e,t,n){if(document.getElementsByClassName){getElementsByClassName=function(e,t,n){n=n||document;var r=n.getElementsByClassName(e),i=t?new RegExp("\\b"+t+"\\b","i"):null,s=[],o;for(var u=0,a=r.length;u<a;u+=1){o=r[u];if(!i||i.test(o.nodeName)){s.push(o)}}return s}}else if(document.evaluate){getElementsByClassName=function(e,t,n){t=t||"*";n=n||document;var r=e.split(" "),i="",s="http://www.w3.org/1999/xhtml",o=document.documentElement.namespaceURI===s?s:null,u=[],a,f;for(var l=0,c=r.length;l<c;l+=1){i+="[contains(concat(' ', @class, ' '), ' "+r[l]+" ')]"}try{a=document.evaluate(".//"+t+i,n,o,0,null)}catch(h){a=document.evaluate(".//"+t+i,n,null,0,null)}while(f=a.iterateNext()){u.push(f)}return u}}else{getElementsByClassName=function(e,t,n){t=t||"*";n=n||document;var r=e.split(" "),i=[],s=t==="*"&&n.all?n.all:n.getElementsByTagName(t),o,u=[],a;for(var f=0,l=r.length;f<l;f+=1){i.push(new RegExp("(^|\\s)"+r[f]+"(\\s|$)"))}for(var c=0,h=s.length;c<h;c+=1){o=s[c];a=false;for(var p=0,d=i.length;p<d;p+=1){a=i[p].test(o.className);if(!a){break}}if(a){u.push(o)}}return u}}return getElementsByClassName(e,t,n)}
</script>

						



<script type="text/javascript">
if (typeof jQuery == 'undefined') { document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.min.js' type='text/javascript'%3E%3C/script%3E")); }


document.documentElement.id = "js";

var site = {
			abbreviation: "",
	        type: "BMC_NICHE",
        portalId: "9001",
                section: "browse",
                page: "fulltext",
    		
									homePortal: "biomedcentral.com",
		
			siteShowAds: "true",
				showAds: "true",
				url: "trialsjournal.com",
			portal: false,
	        adpage_url: "trialsjournal.com/article/10.1186/s13063/015/0597/1",
        id: "10096",
	name: "Trials",
	plugins: {
		scrollable: (getElementsByClassName("scrollable").length > 0),
				flowplayer: ((document.getElementById("flowplayer") != null) || (getElementsByClassName("myPlayer").length > 0) || (document.getElementById("videoarticle") != null) || (getElementsByClassName("flowplayer").length > 0) || (document.getElementById("audio") != null) || (document.getElementById("elifeplayer") != null)),
		lightbox: ((document.getElementById("image-highlight") != null) || (getElementsByClassName("lightbox").length > 0)),
		thickbox: (getElementsByClassName("thickbox").length > 0),
		altmetric: ((document.getElementById("altmetric") != null) || (getElementsByClassName("altmetric").length > 0))
	}
	
};



if(typeof quoteSearchUri == "undefined") { quoteSearchUri=null; }
</script>



        <script type="text/javascript" src="http://www.bmcimg.com/javascript/journals/behaviours-0.js"></script>






		<script>
	if (site.plugins.scrollable == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.scrollable-1.0.1.min.js' %3E%3C/script%3E")); 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.tools.min.js'%3E%3C/script%3E"));
	}

	if (site.plugins.flowplayer == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/flowplayer-3.2.6.min.js'%3E%3C/script%3E"));
	}

	if (site.plugins.lightbox == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/browse_imagehighlight.js'%3E%3C/script%3E"));
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.colorbox.js' %3E%3C/script%3E"));
	}

	if (site.plugins.thickbox == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/thickbox-compressed.js' %3E%3C/script%3E"));
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/thickbox-flashhidden-patch.js' %3E%3C/script%3E"));
	}
	</script>





            <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery.fancybox-1.3.1.pack-0.js"></script>
            <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery.debug-0.js"></script>
                      <script type="text/javascript" src="http://www.bmcimg.com/javascript/email_preferences/email_preferences-0.js"></script>
                <script type="text/javascript" src="http://www.bmcimg.com/javascript/articles/articles-0.js"></script>
		<div id="fb-root"></div>











        <script type="text/javascript" src="/javascript/plugins/jquery.tagcloud.min-0.js"></script>




<!--[if lte IE 6]>
            <script type="text/javascript" src="/javascript/plugins/DD_belatedPNG_0.0.8a-0.js"></script>
    <script type="text/javascript">
        DD_belatedPNG.fix('.png_bg, ul.primary-nav li a, ul.primary-nav li a span, ul.secondary-nav li a, ul.secondary-nav li a span, ul li i, .plus-button, .facebook, .twitter, .fancy-bg, #fancybox-close');
    </script>
	                <link rel="stylesheet" type="text/css" href="http://www.bmcimg.com/css/hacks/ie6-0.css"/>
    <![endif]-->

<!-- Claudia Whitcombe wanted this comment here -->

       <div class="hide">
      <dl class="google-ad" id="x96banner">
        <dt style="display: block;" class="hide">
          <a class="skyscraper-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</a>
       </dt>
        <dd>
          <!-- OAS AD 'x96' begin -->
          <script type="text/javascript">
            OAS_AD('x96');
          </script>
        </dd>
      </dl>
    </div>  
    
</body>
</html>

